Education
About Us
Working with TipRanks
Follow Us
Tectonic Therapeutic (TECX)
NASDAQ:TECX
TECX Stock Chart & Stats
Day’s Range― - ―
52-Week Range$13.70 - $61.07
Previous CloseN/A
Volume30.18K
Average Volume (3M)244.81K
Market Cap
$301.59M
Enterprise Value$545.04M
Total Cash (Recent Filing)$141.24M
Total Debt (Recent Filing)$3.30M
Price to Earnings (P/E)―
Beta1.53
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-8.20
Shares Outstanding18,662,672
10 Day Avg. Volume281,097
30 Day Avg. Volume244,807
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)5778.14
Price to Cash Flow (P/CF)-4.00
P/FCF Ratio0.00
Enterprise Value/Market Cap1.81
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-883.37
Enterprise Value/Ebitda-11.28
Forecast
1Y Price Target
$82.00Price Target Upside407.43% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
---
Tectonic Therapeutic News
See All TECX News
---
Bulls Say, Bears Say
Bulls Say
Clinical TrialsTX45 delivered highly encouraging Ph1b Part A interim results, with full data to be presented at a medical meeting later this year.
Market OpportunityTECX will report Ph1b data in PH-HFrEF, an indication that could potentially double TX45’s market opportunity.
ValuationTECX is undervalued given noise around a competitor's discontinuation of their program in a different indication and some misconceptions around the relaxin mechanism.
Bears Say
Clinical RisksA transient, asymptomatic 5-12 mmHg mean decrease in systemic blood pressure was observed post-IV dosing, which resolved at subsequent visits.
Competitive LandscapeVolenrelaxin is a different molecule with unknowns, and the trial design limits potential negative readthrough.
Stock PerformanceTECX is -52% YTD due to LLY discontinuing their relaxin program and the bear point that TX45 is not an anti-fibrotic.
---
Ownership Overview
35.14% Insiders
3.49% Mutual Funds
24.52% Other Institutional Investors
33.79% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
TECX FAQ
What was Tectonic Therapeutic’s price range in the past 12 months?
Tectonic Therapeutic lowest stock price was $13.70 and its highest was $61.07 in the past 12 months.
What is Tectonic Therapeutic’s market cap?
Tectonic Therapeutic’s market cap is $301.59M.
When is Tectonic Therapeutic’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Tectonic Therapeutic’s earnings last quarter?
Tectonic Therapeutic released its earnings results on Nov 07, 2024. The company reported -$1.2 earnings per share for the quarter, missing the consensus estimate of -$0.84 by -$0.36.
Is Tectonic Therapeutic overvalued?
According to Wall Street analysts Tectonic Therapeutic’s price is currently Undervalued.
Does Tectonic Therapeutic pay dividends?
Tectonic Therapeutic does not currently pay dividends.
What is Tectonic Therapeutic’s EPS estimate?
Tectonic Therapeutic’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Tectonic Therapeutic have?
Tectonic Therapeutic has 18,662,672 shares outstanding.
What happened to Tectonic Therapeutic’s price movement after its last earnings report?
Tectonic Therapeutic reported an EPS of -$1.2 in its last earnings report, missing expectations of -$0.84. Following the earnings report the stock price went down -4.644%.
Which hedge fund is a major shareholder of Tectonic Therapeutic?
Currently, no hedge funds are holding shares in TECX
---
Tectonic Therapeutic Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$82.00 (407.43% Upside)
$82.00 (407.43% Upside)
Hedge Fund Trend
Increased
By 257.3K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $42.5M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Negative
Last 7 Days ▼ 0.3%
Last 30 Days ▼ 0.6%
Last 30 Days ▼ 0.6%
News Sentiment
Neutral
Bullish news 50%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
6.03%
12-Months-Change
Fundamentals
Return on Equity
-42.09%
Trailing 12-Months
Asset Growth
51.25%
Trailing 12-Months
Company Description
Tectonic Therapeutic
Tectonic Therapeutic, Inc., a clinical stage biotechnology company focuses on the discovery and development of therapeutic proteins and antibodies to modulate the activity of G-protein coupled receptors(GPCRs). It offers GEODe technology platform to enable the discovery and development of GPCR-targeted biologic medicines. The company's pipeline products include RXFP1 agonist, which is in ongoing phase 1a and 1b for the indication of heart failure with preserved ejection fraction; GPCR antagonist for indication of hereditary hemorrhagic telangiectasia; bi-functional GPCR modulator for indication of fibrosis; and GPCR modulators. Tectonic Therapeutic, Inc. is based in Watertown, Massachusetts.
---
TECX Stock 12 Month Forecast
Average Price Target
$82.00
▲(407.43% Upside)
Technical Analysis
Inventiva
―
Verve Therapeutics
―
Entrada Therapeutics Inc
―
Amylyx Pharmaceuticals Inc
―
Zenas BioPharma, Inc.
―
Best Analysts Covering TECX
1 Year
1 Year Success Rate
1/5 ratings generated profit
1 Year Average Return
-22.22%
reiterated a buy rating 21 days ago
Copying Tyler Van Buren's trades and holding each position for 1 Year would result in 20.00% of your transactions generating a profit, with an average return of -22.22% per trade.
---